Chiesi Global Rare Diseases Announces Multiple Presentations on pegunigalsidase alfa and Fabry Disease at the 21st Annual WORLDSymposium™ Research Meeting
March 18, 2025
Evaluating the relationship between infusion-related reactions and anti-drug antibody status: Results from 111 patients with Fabry disease treated with pegunigalsidase alfa
Lower rate of infusion-related reactions in patients with Fabry disease after switching from agalsidase beta to pegunigalsidase alfa
Improved tolerability following enzyme replacement therapy switch to pegunigalsidase alfa: a case series from two centers of the expanded access program
Awareness of Fabry disease among non-Fabry specialists; opportunities for education
Clinical assessment of disease severity in patients with Fabry disease treated with pegunigalsidase alfa: An integrated analysis
Indirect treatment comparisons of pegunigalsidase alfa vs other therapies for left ventricular mass index in Fabry disease
Speaking the same language: the Fabry lexicon and the implications for how the healthcare community understands the impact of ERT
Maximising engagement through feedback: insights from shared decision-making toolkit for Fabry disease patients